13.03.2017 – 07:10

AEVIS VICTORIA SA

EQS-Adhoc: AEVIS VICTORIA SA: prise de position sur le Rapport du Conseil d'administration de LifeWatch AG

EQS Group-Ad-hoc: AEVIS VICTORIA SA / Mot-clé(s): Offre d'acquisition
AEVIS VICTORIA SA: prise de position sur le Rapport du Conseil d'administration
de LifeWatch AG

13.03.2017 / 07:05 CET/CEST
Publication d'un communiqué ad hoc en vertu de l'article 53 du RC.
Le contenu relève de la responsabilité de l'émetteur.

--------------------------------------------------------------------------------
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA AND
JAPAN

Communiqué de presse

Fribourg, le 13 mars 2017

AEVIS VICTORIA: prise de position sur le Rapport du Conseil d'administration de
LifeWatch AG

AEVIS VICTORIA SA (AEVIS VICTORIA) a pris connaissance du Rapport du Conseil
d'administration de LifeWatch AG (LifeWatch) concernant l'offre publique
d'acquisition d'AEVIS VICTORIA. Elle regrette que le Comité formé à cette
occasion ait recommandé le rejet de son offre amicale. Il y a un an, le Conseil
d'administration avait pourtant explicitement salué l'entrée d'un potentiel
actionnaire de référence et modifié sa composition en conséquence.

AEVIS VICTORIA relève que le Conseil d'administration de LifeWatch ne fournit
pas d'indications chiffrées précises à l'appui de sa recommandation de rejet de
l'offre et ne fonde pas son appréciation de l'offre sur une expertise
d'évaluation indépendante (Fairness Opinion). Dans le cadre de son offre, AEVIS
VICTORIA avait quant à elle mandaté Ernst & Young afin de réaliser une
évaluation indépendante de la valeur des actions d'AEVIS VICTORIA. L'évaluation
d'Ernst & Young valorise l'offre d'échange faite aux actionnaires de LifeWatch
entre CHF 12.40 et CHF 13.60 par action LifeWatch.

AEVIS VICTORIA est convaincue que LifeWatch a besoin d'un actionnaire de
référence ayant une implantation forte dans le secteur de la santé, qui pourra
lui apporter une vision sur le long terme et les moyens financiers nécessaires
pour développer son modèle d'entreprise.

Suite à l'aboutissement de l'offre, LifeWatch deviendra une filiale d'AEVIS
VICTORIA, gérée de manière indépendante, et permettra à AEVIS VICTORIA de
durablement renforcer ses activités de télémédecine.

Obtention des documents relatifs à l'offre
Le prospectus peut être obtenu auprès d'UBS SA Prospectus Library, Case postale,
8098 Zurich, tél +41 44 239 47 03, fax +41 44 239 69 14, 
e-mailswiss-prospectus@ubs.com.

La documentation peut en outre être consultée à l'adresse :
http://www.aevis.com/websites/aevis/French/3700/autres-informations.html

Pour plus d'informations:
AEVIS VICTORIA SA Presse et Relations Investisseurs: c/o Dynamics Group, Zurich
Philippe R. Blangey,  prb@dynamicsgroup.ch, +41 (0) 43 268 32 35 ou +41 (0) 79
785 46 32
Séverine Van der Schueren,  svanderschueren@aevis.com, +41 (0) 26 350 02 02

AEVIS VICTORIA SA - Investing for a better life
AEVIS VICTORIA SA investit dans les services à la personne, le healthcare,
l'hôtellerie, les sciences de la vie et le lifestyle. Les principales
participations d'AEVIS sont Swiss Medical Network, le 2e groupe d'hôpitaux
privés en Suisse, Victoria-Jungfrau Collection AG, chaine hôtelière exploitant
cinq palaces en Suisse, un segment immobilier comprenant 40 immeubles médicaux
et d'hôtels, Medgate, le leader incontesté dans le domaine de la télémédecine en
Suisse et NESCENS SA, une marque dédiée à la prévention et au better aging.
AEVIS est coté sur le segment Swiss Reporting de SIX Swiss Exchange (AEVS.SW).
www.aevis.com.

RESTRICTIONS A L'OFFRE

En général
L'offre mentionnée dans ce communiqué de presse n'est faite ni directement ni
indirectement dans un Etat ou une juridiction dans lequel/laquelle une telle
offre serait illicite ou contreviendrait de toute autre manière aux lois ou
réglementations en vigueur ou qui exigerait de la part de l'offrant une
modification des termes ou des conditions de l'offre de quelque manière que ce
soit ou la formulation d'une requête ou la réalisation de démarches
supplémentaires auprès d'autorités gouvernementales, d'autorégulation ou
d'autres organes en relation avec l'offre. Il n'est pas prévu d'étendre l'offre
à de tels Etats ou à de telles juridictions. La documentation relative à l'offre
ne doit pas être distribuée ou envoyée dans de tels Etats ou dans de telles
juridictions. Cette documentation ne doit pas non plus être utilisée pour
solliciter l'acquisition de titres de participation de LifeWatch de personnes
domiciliées ou ayant leur siège dans de tels Etats ou dans de telles
juridictions.

United States of America
The public tender offer described in this press release is not made directly or
indirectly in or by use of the mail of, or by any means or instrumentality of
interstate or foreign commerce of, or any facilities of a national securities
exchange of, the United States of America and may only be accepted outside the
United States of America. This includes, but is not limited to, facsimile
transmission, telex or telephones. This press release and any offering materials
with respect to the public tender offer described in this press release may not
be distributed in nor sent to the United States of America and may not be used
for the purpose of soliciting the sale or purchase of any securities of
LifeWatch from anyone in the United States of America. The offeror will not be
soliciting the tender of securities of LifeWatch by any holder of such
securities in the United States of America. Securities of LifeWatch will not be
accepted from holders of such securities in the United States of America. Any
purported acceptance of the offer that the offeror or its agents believe has
been made in or from the United States of America will be invalidated. The
offeror reserves the absolute right to reject any and all acceptances determined
by them not to be in the proper form or the acceptance of which may be unlawful.

The securities to be issued pursuant to the public tender offer described in
this press release have not been and will not be registered under the U.S.
Securities Act of 1933, as amended (the "U.S. Securities Act"), nor under any
law of any state of the United States of America, and may not be offered, sold,
resold, or delivered, directly or indirectly, in or into the United States of
America, except pursuant to an exemption from the registration requirements of
the U.S. Securities Act and the applicable state securities laws. Neither this
press release nor the public tender offer described in this press release does
constitute an offer to sell or the solicitation of an offer to buy any
securities in the United States of America or in any other jurisdiction in which
such an offer or solicitation would be unlawful. Securities may not be offered
or sold in the United States of America absent registration or an exemption from
registration. AEVIS will not register or make a public offer of its securities,
or otherwise conduct the public tender offer, in the United States of America.

United Kingdom
This communication is directed only at persons in the U.K. who (i) have
professional experience in matters relating to investments, (ii) are persons
falling within article 49(2)(a) to (d) ("high net worth companies,
unincorporated associations, etc") of The Financial Services and Markets Act
2000 (Financial Promotion) Order 2005 or (iii) to whom it may otherwise lawfully
be communicated (all such persons together being referred to as "relevant
persons"). This communication must not be acted on or relied on by persons who
are not relevant persons. Any investment or investment activity to which this
communication relates is available only to relevant persons and will be engaged
in only with relevant persons.

Australia, Canada, Japan
The public tender offer described in this press release is not addressed to
shareholders of LifeWatch whose place of residence, seat or habitual abode is in
Australia, Canada or Japan, and such shareholders may not accept the offer.

European Economic Area
The public tender offer described in this press release (the "Offer") is only
being made within the European Economic Area ("EEA") pursuant to an exemption
under Directive 2003/71/EC (as amended and together with any applicable adopting
or amending measures in any relevant member state (as defined below), the
"Prospectus Directive"), as implemented in each member state of the EEA (each a
"relevant member state"), from the requirement to publish a prospectus that has
been approved by the competent authority in that relevant member state and
published in accordance with the Prospectus Directive as implemented in that
relevant member state or, where appropriate, approved in another relevant member
state and notified to the competent authority in that relevant member state, all
in accordance with the Prospectus Directive. Accordingly, in the EEA, the Offer
and documents or other materials in relation to the offer and the shares in
AEVIS (the "Offeror Shares") are only addressed to, and are only directed at,
(i) qualified investors ("qualified investors") in the relevant member state
within the meaning of Article 2(1)(e) of the Prospectus Directive, as adopted in
the relevant member state, and (ii) persons who hold, and will tender, the
equivalent of at least EUR 100,000 worth of shares in LifeWatch (the "Target
Shares") in exchange for the receipt of offeror Shares (collectively, "permitted
participants"). This press release and the documents and other materials in
relation to the offer may not be acted or relied upon by persons in the EEA who
are not permitted participants, and each shareholder of LifeWatch seeking to
participate in the offer that is resident in the EEA will be deemed to have
represented and agreed that it is a qualified investor or that it is tendering
the equivalent of EUR 100,000 worth of Target Shares in exchange of offeror
Shares.

--------------------------------------------------------------------------------
Fin du communiqué ad hoc--------------------------------------------------------

553201  13.03.2017 CET/CEST